Table 1.

Baseline Study Sample Characteristics

Characteristic	Age Group (years)								Total
	≤ 55		56-65		66-75		> 75
	No.	%	No.	%	No.	%	No.	%	No.	%
Race/ethnicity
Latino	26	2	74	2	82	2	13	1	195	2
African American	200	14	508	13	429	9	79	5	1,216	10
White	1,158	82	3,336	83	4,083	87	1,585	93	10,162	86
Other	27	2	87	2	73	2	30	2	217	2
Comorbidities
0	308	22	646	16	528	11	142	8	1,624	14
1	352	25	895	22	931	20	264	15	2,442	21
2	220	16	740	18	995	21	362	21	2,317	20
3	102	7	437	11	708	15	295	17	1,542	13
> 3	51	4	340	8	574	12	276	16	1,241	11
Missing	378	27	947	24	931	20	368	22	2,624	22
PSA at diagnosis, ng/mL
0-10	1,121	79	2,908	73	3,056	65	864	51	7,949	67
> 10-20	136	10	513	13	818	18	425	25	1,892	16
> 20-30	19	1	105	3	209	4	113	7	446	4
> 30	44	3	178	4	243	5	177	10	642	5
Missing	91	6	301	7	341	7	128	8	861	7
Gleason score
2-6	1,011	72	2,623	65	2,813	60	805	47	7,252	62
3 + 4	213	15	613	15	732	16	318	19	1,876	16
4 + 3	71	5	278	7	406	9	188	11	943	8
8-10	67	5	272	7	413	9	262	15	1,014	9
Missing	49	3	219	5	303	6	134	8	705	6
Clinical stage
T1	744	53	1,959	49	2,034	44	630	37	5,367	46
T2a/b	357	25	1,090	27	1,404	30	536	31	3,387	29
T2c	231	16	673	17	857	18	406	24	2,167	18
T3a	16	1	69	2	132	3	60	4	277	2
Missing	64	4	214	5	240	5	75	4	592	5
Percent positive biopsy
≤ 10	156	11	424	11	514	11	159	9	1,253	11
11-33	514	36	1,364	34	1,534	33	494	29	3,906	33
34-50	386	27	980	24	1,111	24	411	24	2,888	25
51-75	114	8	368	9	418	9	155	9	1,055	9
> 75	128	9	432	11	504	11	220	13	1,284	11
Missing	113	8	437	11	586	13	268	16	1,404	12
Treatment
RP	1,197	85	2,801	70	1,810	39	47	3	5,855	50
Cryotherapy	15	1	129	3	263	6	51	3	458	4
Brachytherapy	81	6	441	11	789	17	241	14	1,552	13
EBRT	45	3	290	7	804	17	350	21	1,489	13
PADT	49	3	232	6	661	14	696	41	1,638	14
WW	24	2	112	3	340	7	322	19	798	7
Total	1,411		4,005		4,667		1,707		11,790

Abbreviations: PSA, prostate-specific antigen; RP, radical prostatectomy; EBRT, external-beam radiation therapy; PADT, primary androgen deprivation therapy; WW, watchful waiting.